On November 30, 2021 NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, reported that the preclinical data on naptumomab estafenatox (NAP) enhancing the potency of CAR-T cells was presented on Nov 12th at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 36th Annual Meeting at the Walter E. Washington Convention Center, Washington D.C. (Press release, NeoTX, NOV 30, 2021, View Source [SID1234640356]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Clinical CAR-T therapy currently has limited efficacy against solid tumors due to low trafficking to the tumor, limited cell expansion in patients, tumor antigen heterogeneity, and an immunosuppressive microenvironment. NeoTX presented data that shows that NAP generates more potent CAR-T cells and acts synergistically against tumor cell lines in vitro. NAP is a fusion protein that consists of genetically engineered Superantigens (Sag) linked to Fragment antigen-binding (Fab) moieties directed to tumor-associated antigens, turns "cold tumors hot" and, in preclinical models, can lead to long-term memory responses.

The ability of NAP administration to activate T cells outside of the immunosuppressive microenvironment, promote T cell infiltration into the tumor and induce long-term memory responses strongly suggests that the combination of CAR-T cells with NAP may overcome the limited effect of CAR-T therapy against solid tumors. To access the presented poster, please click here.